Takafumi Ide, M. Chiney, Huynh Yen Thanh Bach, V. Goti, B. Murthy, C. Hobar, Qihong Zhao, U. Aras
{"title":"deucravacitinib是一种口服、选择性、变构性TYK2抑制剂,用于系统性红斑狼疮患者的LP-182药代动力学、选择性特征和暴露-反应关系的疗效和安全性研究","authors":"Takafumi Ide, M. Chiney, Huynh Yen Thanh Bach, V. Goti, B. Murthy, C. Hobar, Qihong Zhao, U. Aras","doi":"10.1136/lupus-2023-kcr.257","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":359413,"journal":{"name":"E-Poster Presentation","volume":"4 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"LP-182 Pharmacokinetics, selectivity profile, and exposure-response relationship for efficacy and safety in a phase 2 study of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with systemic lupus erythematosus\",\"authors\":\"Takafumi Ide, M. Chiney, Huynh Yen Thanh Bach, V. Goti, B. Murthy, C. Hobar, Qihong Zhao, U. Aras\",\"doi\":\"10.1136/lupus-2023-kcr.257\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":359413,\"journal\":{\"name\":\"E-Poster Presentation\",\"volume\":\"4 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"E-Poster Presentation\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/lupus-2023-kcr.257\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"E-Poster Presentation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/lupus-2023-kcr.257","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
LP-182 Pharmacokinetics, selectivity profile, and exposure-response relationship for efficacy and safety in a phase 2 study of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with systemic lupus erythematosus